Product facts, index levels and pricing tiers are as of August 12–16, 2026, taken from Silicon Data’s own product pages, documentation and press releases; the October 5 CME listing remains pending regulatory review, and forward-looking statements depend on filings not yet public. The commodity-market analogies — Platts for the spot assessment, assay grading, reserve engineering — are interpretive frameworks of ours, not claims of regulatory equivalence and not the company’s own framing. The application matrix and routing table are analytical judgments rather than recommendations, and severity assessments assume the products perform as documented. Methodology findings are carried forward from our August 1 study and have not been cured since: the indices are built from posted and quoted rates rather than executed transactions, and the aggregation statistic, weights, outlier rules, contributor list and reference configuration are undisclosed. The conflicts discussion states public facts about corporate relationships and asserts no impropriety by any firm or individual; no conduct finding is made or implied. Nothing here is a recommendation of any vendor, index, venue or instrument, and we hold no position in any of them. Research and education, not investment advice.